Table 4.
Histology of precursor development or progression
|
Development history (n = 89) |
Screening intervals (months) | Median (months) |
|---|---|---|
| Chronic inflammation (4) → Bch (4) | 7, 8, 16, 24 | 8 |
| Chronic inflammation (32) → mD (32) | 6†4, 7†2, 8†4, 12†2, | 21 |
|
13, 17, 19, 21†2, 22, 23, 24, 26, 29, 31, 43†4, 48, 26,30,32,36 |
||
| Chronic inflammation (8) → MD (8) | 6†3, 28†2, 29, 43†2 | 28 |
| Chronic inflammation (4) → SD (4) | 13, 23, 44, 39 | 33.5 |
| Bch (2) → Cis (2) | 7, 18 | 12.5 |
| Bch (1) → cancer (T2N0M0) (1) | 52 | |
| mD (6) → MD (6) | 6, 8†2, 13, 16, 25 | 10.5 |
| mD (8) → SD (8) | 6†3, 10.5, 13, 16†2, 23 | 11.8 |
| MD (6) → SD (6) | 6, 9, 10, 13, 18, 48 | 10 |
| MD (9) → Cis (9) | 6, 6, 9, 13†2, 18, 35, 44, 50 | 13 |
| MD (1) → cancer (T2N0M0) (1) | 46 | |
| SD (8) → submucosal carcinoma (8) | 6†2, 7, 18, 19, 34, 36, 48 | 12 |
†
Patient developed mD from chronic inflammation in six months.
Bch, basal cell hyperplasia; Cis, carcinoma in situ; mD, mild dysplasia; MD, moderate dysplasia; SD, severe dysplasia; UGIC, upper gastrointestinal cancer.